Fig. 2

FGF2 caused paradoxical proliferation can be reversed using specific FGFR inhibitors. A. Spheroids images formed by FGFR1 amplified cells (CAMA1 and MDA-MB-134) and non-amplified cells (MCF7 and T47D) when incubated with FGFR inhibitors PD166866 (FGFR1i, 1.0µM), Alofanib (FGFR2i, 1.0µM), H3B-6527 (FGFR4i, 1.0µM), and AZD4547 (FGFR1-3i, 1.0µM) in the presence or absence of FGF2 for 14 days. Bar equals 1000 μm. B. Relative fold change of ratio between cell number in + FGF2 vs. -FGF2 spheroids for each treatment in Panel A. The ratios in the DMSO control group are serving as controls and set as a fold of one. C. Immunoblotting shows the levels of p21 and CCND1 expression, as well as the phosphorylation of Stat1/3 and Erk1/2 in ER + cell 3D cultures that were incubated with specific FGFR inhibitors (1.0µM for all inhibitors) and FGF2 (25ng/mL) for 72 h